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Summary
Cutaneous squamous cell carcinoma (cSCC) is a serious complication after 
organ transplantation and patients benefit from an early risk assessment. 
We hypothesized that functional differences in circulating T cells may 
represent risk factors for post-transplant cSCC development. Here, we 
analysed genome-wide DNA methylation of circulating T cells of kidney 
transplant recipients before the clinical onset of cSCC, to identify differ-
ences associated with post-transplant cSCC development. This analysis 
identified higher DNA methylation of SERPINB9, which is an intracellular 
inhibitor of granzyme B, a protein that induces apoptosis in target cells. 
High DNA methylation of SERPINB9 in circulating T cells was confirmed 
in a second patient cohort during recurrent cSCC, indicating that high 
SERPINB9 methylation represents a persistent risk factor for cSCC devel-
opment. At the functional level, the inverse correlation between DNA 
methylation and messenger RNA expression present in non-cSCC patients 
was absent in the cSCC patients. Also, a significant difference in serpinB9 
protein expression between cSCC patients and non-cSCC patients was 
observed. It was concluded that disturbed regulation of serpinB9 in cir-
culating T cells represents a novel risk factor for post-transplant cSCC in 
kidney transplant recipients.
Keywords: cutaneous squamous cell carcinoma, DNA methylation, 
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Introduction
Immunosuppression after organ transplantation is associ-
ated with a higher prevalence of cancer [1,2]. Non-
melanoma skin cancer, in particular, such as cutaneous 
squamous cell carcinoma (cSCC), can occur up to 200 
times more in transplant patients compared to the general 
population [3–5]. Transplant recipients also experience 
more metastasis and more than 70% of the patients develop 
a subsequent cSCC within 5  years [6]. Although immu-
nosuppressive treatment is recognized as an important 
risk factor for the development of cSCC after solid organ 
transplantation, little is known on the immune regulation 
leading up to formation of cSCC.
Most cSCCs are surrounded by immune cell infiltrates; 
however, these cells are incapable of mounting an effec-
tive immune response directed against the cSCC [7]. 
The role and phenotype of T cells surrounding an cSCC 
lesion has been studied extensively [8–10]; high numbers 
of forkhead box protein 3 (FoxP3)+ regulatory T cells 
are associated with higher metastasis of cSCCs [11,12], 
whereas increased activity of effector and cytotoxic T 
cells often associates with better prognostic outcomes 
[13,14].
The function of cells, including T cells, is regulated by 
epigenetic mechanisms such as DNA methylation, which is 
the addition of a methyl group to a cytosine (C) followed 
by a guanine (G; CpG dinucleotide) in the DNA. DNA 
methylation controls gene expression, is a dynamic feature 
and can be influenced by environmental cues [15]. DNA 
methylation is also known to be dysregulated in disease 
such as cancer; however, it is often difficult to determine 
whether it is a driver or a consequence of the disease [16,17].
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Here, we hypothesized that functional differences in 
circulating T cells represent risk factors in the develop-
ment of a de-novo post-transplant cSCC. To address 
this hypothesis, we took an unbiased approach and 
performed genomewide DNA methylation analysis of 
circulating T cells after kidney transplantation but before 
the clinical onset of cSCC (discovery phase). DNA 
methylation profiles of kidney transplant recipients with 
a future cSCC were compared to those of matched 
kidney transplant recipients without cSCC. The promi-
nent finding of this analysis was higher methylation of 
a region within SERPINB9 in cSCC patients. SerpinB9 
is an intracellular serine protease inhibitor that inhibits 
granzyme B [18,19], which is an important protease in 
the effector function of cytotoxic T cells by inducing 
apoptosis in target cells [20]. Cytotoxic T cells express 
serpinB9 to protect themselves against the activity of 
granzyme B, and studies have shown that high expres-
sion of serpinB9 in cytotoxic T cells makes them more 
potent killers [21,22]. Given these data, the finding on 
SERPINB9 DNA methylation prompted us to further 
study SERPINB9 methylation in a second cohort of 
kidney transplant recipients with recurrent cSCC, as 
well as the functional role of SERPINB9 in cSCC on 
the level of mRNA and protein expression.
Materials and methods
Study design
Anonymized retrospective biobank samples were used in 
the discovery phase of the study; this included kidney 
transplant recipients before the diagnosis of their first 
post-transplant cSCC. A second cohort of patients was 
used to confirm findings from the discovery phase, and 
this included kidney transplant recipients during recurrent 
post-transplant cSCC. The use of biobank material and 
the inclusion of new patients was approved by the local 
medical ethical committee (MEC-2015-642). All kidney 
transplant recipients with a (future) post-transplant cSCC 
were matched to kidney transplant recipients who did 
not develop an cSCC within a similar time-period after 
the first transplant. Matching criteria included gender, 
age (±  4 years), ethnicity, cytomegalovirus (CMV) status 
and type of immunosuppressive drugs directly after trans-
plantation. We included patients with at least one cSCC 
after transplantation and patients with cSCC in situ 
(Bowen’s disease). Patients with another donor organ such 
as liver, heart or lung were excluded, as well as patients 
with a history of malignancy prior to transplantation. 
Non-cSCC patients with actinic keratosis, a precancerous 
lesion, were also excluded.
T cell isolation
Peripheral blood mononuclear cells (PBMCs) were iso-
lated using standard Ficoll-Paque procedures. T cells 
were isolated from the PBMCs using fluorescence-acti-
vated cell sorting (FACS) with the BD FACSAriaTM ll 
(BD Biosciences, San Jose, CA, USA). Total PBMCs 
were stained with CD3 Brilliant Violet 510 (Biolegend, 
San Diego, CA, USA), CD4 Pacific Blue (BD Biosciences), 
CD8 allophycocyanin-cyanin 7 (APC-Cy7) (BD 
Biosciences), CD45RO APC (Biolegend), CCR7 phyco-
erythrin (PE)-Cy7 (BD Biosciences), CD25 PE (BD 
Biosciences), CD127 fluorescein isothiocyanate (FITC) 
(eBioscience, Waltham, MA, USA) and to exclude non-
viable cells Via-Probe 7-aminoactinomycin D (7AAD) 
(BD Biosciences) was used. After cell sorting the purities 
were >  96% for CD3+ cells; samples below 95% were 
excluded for further analysis.
Genomewide DNA methylation arrays
Before isolating DNA from the T cells in the discovery 
cohort, all patient samples were randomized to minimize 
batch effects. DNA was isolated using the QIAamp 
DNA Micro kit (Qiagen, Venlo, the Netherlands), accord-
ing to the manufacturer’s protocol. Purity and concen-
tration of the isolated DNA was assessed with the 
NanoDrop ND-8000 (Isogen Life Science, Utrecht, the 
Netherlands). DNA degradation was determined by gel 
electrophoresis. None of the samples showed a significant 
degradation.
The Infinium Human Methylation 450 arrays (Illumina, 
San Diego, CA, USA) were performed as described previ-
ously [23]. Data quality was examined using the MethylAid 
R package [24,25] and all samples passed quality controls 
using the default MethylAid thresholds. Probes with a 
detection P-value > 0·01, probes containing single nucleo-
tide polymorphisms and probes on the sex chromosome 
were removed from the data set. A between-array nor-
malization was applied to the types Ι and ΙΙ probes sepa-
rately using the DASEN method within the wateRmelon 
Bioconductor r package [25–27]. The methylation level 
of a CpG site is presented as a beta-value, a value between 
0 (unmethylated) and 1 (fully methylated). After the qual-
ity controls and normalization, beta-values of 423  289 
CpG sites remained for further analysis. Both the raw 
and normalized data are available via the NCBI Gene 
Expression Omnibus (GEO) database with Accession num-
ber GSE117050.
Data analysis DNA methylation arrays
To identify DNA methylation differences between the 
future cSCC and non-cSCC patients, we performed the 
data analysis as previously described [23]. First, a linear 
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mixed-effect model was performed using the lme4 r pack-
age [28]. The fixed effects included age, percentage of 
CD4, percentage of CD8 and CMV status. Percentages 
of CD4 and CD8 were included to correct for differences 
in T cell composition between individuals, and CMV is 
known to affect DNA methylation at specific genes [29]. 
Array IDs were included as a random effect to account 
for technical variation between the arrays. This resulted 
in single site-specific P-values and these P-values, together 
with their genomic location, were used as input into 
comb-p [30] to find differentially methylated regions 
(DMRs). A sliding window of 500 base pairs (bp) was 
used and the seed was set at P  <  0·01. A stringent mul-
tiple testing correction was applied using a Šidák correc-
tion (Šidák  <  0·05) [31].
DNA methylation analysis by pyrosequencing
After the discovery phase we continued measuring DNA 
methylation of T cells with bisulphite pyrosequencing, 
an easy technique to quantitatively measure single-site 
DNA methylation [32], but first we tested whether 
pyrosequencing resulted in the same methylation values 
as the microarrays. Therefore, CpG sites within DMR 
1 (SERPINB9) and DMR 2 (VTRNA2-1) were analysed 
in the same DNA samples that were used for the array 
analysis of 10 patients, a mixture of cSCC and non-
cSCC patients.
Pyrosequencing was performed as described previously 
[23,33]. The polymerase chain reaction (PCR) primers, 
melting temperatures and amplicon sizes for the different 
PCR products can be found in the Supporting informa-
tion, Table S1 together with the specific PCR programmes. 
For SERPINB9, 12  CpG sites, five of which were array 
probes, were sequenced in two separate reactions and 
DNA methylation was averaged per sequence reaction 
(regions 1 and 2). For VTRNA2-1, five CpG sites, three 
of which were array probes, were measured and an aver-
age of those five sites is presented in the results.
mRNA analysis
Total RNA was isolated from T cells using the High Pure 
RNA Isolation kit (Roche Applied Science, Pennsburg, 
Germany), according to the manufacturer’s protocol. The 
quality and purity of the RNA was assessed using the 
NanoDrop ND-8000 (Isogen Life Science). Samples with 
a 260/280 ratio below 1·8 and a 260/230 ratio above 1 
were excluded for further analysis. Messenger RNA 
(mRNA) of SERPINB9 and GRANZYME B (GZMB) was 
quantified by real-time quantitative PCR (qPCR) using a 
Taqman gene expression assay. Primers used were 
Hs00394497_m1 (SERPINB9; Thermo Fisher Scientific, 
Waltham, MA, USA) and Hs01554355_m1 (GZMB; 
Thermo Fisher Scientific), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (Hs99999905_m1, Thermo 
Fisher Scientific) was used as housekeeping gene. qPCR 
was performed on the StepOnePlus Real-Time PCR system 
(Applied Biosystems). Gene expression was then calculated 
by transforming the cycle threshold (Ct) to cDNA copies 
(240–Ct). Dividing the number of SERPINB9 and GZMB 
copies by the number of GAPDH copies resulted in a 
relative gene expression value.
Protein analysis
Protein levels of serpinB9 and granzyme B within T cells 
were assessed in cells before and after stimulation for 
6  h at 37°C with or without α-CD3/CD28-coated 
Dynabeads® (Gibco, Waltham, MA, USA). The cells were 
measured by flow cytometry directly after defrosting the 
PBMCs. Monensin was added after 1  h of stimulation, 
whereby this newly synthesized granzyme B could be 
measured. CD107a APC (BD Biosciences) was added to 
the cell cultures to assess degranulation of the cells. Cells 
were stained with the following surface antibodies: CD3 
Brilliant Violet 510 (Biolegend), CD4 APC-Cy7 
(Biolegend), CD8 PE (Thermo Fisher Scientific) and Via-
Probe 7AAD (BD Biosciences) was used to exclude non-
viable cells. After surface staining the cells were fixed, 
permeabilized and stained for intracellular serpinB9 labelled 
with Alexa Fluor 488 (Bio-rad, Hercules, CA, USA) and 
granzyme B labelled with Brilliant Violet 421 (BD 
Biosciences). Isotype controls for AF488 (Bio-Rad) and 
BV421 (BD Biosciences) were used as negative controls 
for serpinB9 and granzyme B expression. The cells were 
then analysed on the FACSCanto ll (BD Biosciences) with 
FACSDiva software. Data were analysed blind, without 
knowledge of cSCC status of the samples, using Kaluza 
software 1.5a (Beckman Coulter, Brea, CA, USA).
Statistical analysis
Differences in clinical characteristics, DNA methylation, 
mRNA and protein expression between the cSCC and 
non-cSCC patients were statistically tested using spss ver-
sion 21.0 (IBM Corp., Armonk, NY, USA). The Mann–
Whitney U-test was used for the continuous variables 
and χ2 test for the categorical variables. Data processing 
and statistical analysis of all the microarray data was 
performed in RStudio version 1.0.136 (RStudio Inc., Boston, 
MA, USA) with r version 3.2.5 [26]. Multiple testing 
correction of the microarray data was performed using 
a Šidák correction (Šidák < 0·05) [31]. Correlation between 
the DNA methylation levels quantified by pyrosequencing 
and the beta-values of the Illumina 450k arrays was cal-
culated using Spearman’s rank correlation coefficient using 
spss, as well as correlations between DNA methylation 
and mRNA expression. All statistical tests were two-tailed 
and a P  <  0·05 was considered statistically significant.
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Results
Patients
The discovery cohort was comprised of 19 future cSCC 
and 19 non-cSCC patients who had been transplanted 
between 1997 and 2012. All patients in the discovery cohort 
were Caucasian European. No statistical differences were 
found between the patient characteristics of the future cSCC 
and non-cSCC patients (Table 1). The T cell subpopulations 
measured during FACS sorting were also not different 
between future cSCC and non-cSCC patients (data not 
shown). A detailed overview of the time between trans-
plantation, sample and first diagnosis of cSCC can be found 
in the Supporting information, Fig. S1a.
The second cohort consisted of 37 non-cSCC and 45 
cSCC patients during recurrent cSCC, who had been trans-
planted between 1976 and 2014. Six cSCC patients and five 
non-cSCC patients received a second kidney transplant. All 
patients in the second cohort were Caucasian European. 
There was a small statistical difference in the end-stage 
renal disease (ESRD) diagnosis between the cSCC and non-
cSCC patients (P  =  0·04; Table 2); no other statistical dif-
ferences were found. The T cell subpopulations measured 
during FACS sorting were not different between cSCC and 
non-cSCC patients (data not shown). A detailed overview 
of the time between transplantation, sample and first diag-
nosis of cSCC can be found in the Supporting information, 
Fig. S1b.
Discovery of significant DMRs in circulating T cells 
before cSCC
To identify differentially methylated regions (DMRs) in 
circulating T cells associated with future cSCC develop-
ment, we compared genomewide DNA methylation of 
kidney transplant recipients with and without a post-
transplant cSCC, before the clinical onset of the cSCC. 
None of the single-site CpGs were statistically significant 
after multiple testing correction. However, we found seven 
regions significantly differentially methylated. In Table 3 
the different DMRs, the genes annotated to these DMRs 
based on genomic location, the genomic location of the 
DMRs according to the hg19 genome build (UCSC Genome 
Browser), the number of probes (CpG sites on the array) 
within the regions and the effect size are presented. Of 
the significant DMRs, five were hypermethylated and two 
were hypomethylated in the future cSCC patients.
Genomic characteristics of DMR 1, 2 and 3
To understand the potential regulatory effect of the DMRs 
in T cells, the genomic location of the DMR and char-
acteristics of that location are important. In Fig. 1, we 
visualized the top three DMRs with DNA methylation 
of both cSCC and non-cSCC patients expressed as beta-
value, the genomic location of the DMRs and the primary 
T cell-specific chromatin state, which is a cell type-specific 
combination of epigenetic features obtained from the 
ROADMAP reference data [34]. DMR 1, annotated to 
SERPINB9, is located intragenically and within an actively 
transcribed region (Fig. 1a). DMR 2, annotated to 
VTRNA2-1, is located in the coding region and a bivalent/
poised transcription start site (TSS) of the gene (Fig. 1b). 
DMR 3, also annotated to VTRNA2-1, is located further 
away from the VTRNA2-1 gene, partly within a bivalent 
enhancer region and partly within a repressed area (Fig. 
1b). All three DMRs overlap with a CpG island and those 
are often involved in the regulation of gene expression.
Table 1. Patient characteristics of the discovery cohort before cSCC
cSCC Non-cSCC
n = 19 n = 19
Age (years)a 64·8 (45–77) 63·5 (45–80) P = 0·49
Gender (male) 14 (73·7%) 14 (73·7%) P = 1
Years post-Txa 1·5 (0·1–6·9) 1·3 (0·1–6·3) P = 0·93
Years between Tx and first 
cSCCa 
5·4 (0·9–12·5) –
Biopsy-proven rejection – 3 (15·8%) P = 0·07
Immunosuppressive treatment
Induction therapy  
(ATG/basiliximab)
7 (36·8%) 5 (26·3%)
Calcineurin inhibitors 
(tacrolimus/cyclosporin)
19 (100%) 18 (94·7%)
Proliferation inhibitors 
(MMF/sirolimus)
18 (94·7%) 19 (100%)
Anti-metabolites 
(azathioprine)
1 (5·3%) –
Corticosteriods 18 (94·7%) 19 (100%)
HLA mismatchesa 3·11 (0–6) 3·11 (0–6) P = 0·94
CMV serostatus acceptor P = 1
Negative 4 (21·1%) 4 (21·1%)
Positive 15 (78·9%) 15 (78·9%)
CMV serostatus donor P = 0·11
Negative 12 (63·2%) 7 (36·8%)
Positive 7 (36·8%) 12 (63·2%)
ESRD diagnosis P = 0·26
Polycystic kidney 7 (36·8%) 2 (10·5%)
Hypertension 3 (15·8%) 6 (31·6%)
Diabetic nephropathy 1 (5·3%) 1 (5·3%)
Glomerulonephritis 1 (5·3%) 0 (0%)
Other 7 (36·8%) 10 (52·6%)
Dialysis pretransplantation P = 0·49
Yes (PD/HD) 14 (73·7%) 12 (63·2%)
No 5 (26·3%) 7 (36·8%)
aMedian and range.
cSCC = cutaneous squamous cell carcinoma; Tx =  transplantation; 
ATG  =  anti-thymocyte globulin; MMF  =  mycophenolate mofetil; 
HLA  =  human leucocyte antigen; CMV  =  cytomegalovirus; ESDR  =   
end-stage renal disease; PD = peritoneal dialysis; HD = haemodialysis.
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Confirmation of microarray methylation values by 
pyrosequencing
To confirm that the above-described findings can also be 
found with a different technique, DNA methylation of DMRs 
1 and 2 was measured by pyrosequencing in the same 
DNA samples. Correlation between DNA methylation values 
obtained with the microarray and pyrosequencing was strong 
in both DMRs (Supporting information, Fig. S2). Spearman’s 
r for SERPINB9 was 0·86 (P  <  0·0001) and for VTRNA2-1 
Spearman’s r was 0·96 (P  <  0·0001). As a result of this 
strong correlation, we measured DNA methylation with 
pyrosequencing throughout the rest of the study.
High intragenic SERPINB9 methylation during cSCC
To assess the stability of the DNA methylation profiles 
identified before the development of cSCC, we included 
a second patient cohort during recurrent cSCC (Table 
2). VTRNA2-1 was measured and was not significantly 
different between cSCC and non-cSCC patients (data not 
shown). When SERPINB9 was measured, it was signifi-
cantly different between cSCC and non-cSCC patients. 
Median DNA methylation of SERPINB9 was 58·7% (range: 
32·5–81·3%) for region 1 and 54·4% (30·0–78·5%) for 
region 2 in the cSCC patients and 50·2% (21·8–77·5%) 
for region 1 and 46·4% (22·1–74·0%) for region 2 in the 
non-cSCC patients (region 1: P  =  0·004; region 2: 
P  =  0·008) (Fig. 2).
Similarly to our discovery cohort, cSCC patients dem-
onstrated higher SERPINB9 methylation values than non-
cSCC patients. In addition, serpinB9 has a strong relation 
to T cell function as a regulator of cytotoxicity [21,22]. 
Together, these findings warranted further investigation 
into the role of SERPINB9 in controlling the cytotoxic 
T cells that are key for immunosurveillance in post-
transplant cSCC.
mRNA expression negatively correlates to DNA 
methylation only in the non-cSCC patients
To study the translation from DNA to protein of serpinB9, 
we analysed mRNA expression of SERPINB9 in T cells. 
Relative mRNA expression of SERPINB9 was not signifi-
cantly different between cSCC (n  =  30) and non-cSCC 
patients (n = 27; Fig. 3a). When we zoomed in and studied 
the correlation between DNA methylation and mRNA 
expression of SERPINB9 in the total patient population 
this was statistically significant (P  =  0.004, Fig. 3b). 
However, when we stratified the data by cSCC status, 
the correlation remained significant only in the non-cSCC 
patients (P  =  0·0003; Fig. 3c,d) and not in the cSCC 
patients, indicating a disrupted transcriptional regulation 
in the cSCC patients.
Lower serpinB9 expression in circulating T cells of 
cSCC patients
To investigate the functional impact of differentially meth-
ylated SERPINB9 on cytotoxicity, we analysed the expres-
sion of the following markers: granzyme B (inhibited by 
serpinB9) and degranulation of T cells by CD107a expres-
sion before and after stimulation. Gating strategies for 
granzyme B and CD107a are presented in the Supporting 
information, Fig. S3. The percentage of CD3+ granzyme 
Table 2. Patient characteristics of the second cohort during cSCC
cSCC Non-cSCC
n = 45 n = 37
Age (years)a 66·4 (34–84) 64·0 (28–75) P = 0·20
Gender (male) 30 (66·7%) 25 (67·6%) P = 0·93
Years post-Txa 8·5 (0·4–40·5) 9·5 (0·1–35·9) P = 0·89
Years between Tx and first 
cSCCa 
4·7 (0–33) –
Biopsy proven rejection 12 (26·7%) 13 (35·1%) P = 0·41
Immunosuppressive treatment
Induction therapy  
(ATG/basiliximab)
1 (2·2%) 6 (16·2%)
Calcineurin inhibitors 
(tacrolimus/
cyclosporin)
37 (82·2%) 34 (92%)
Proliferation inhibitors 
(MMF/sirolimus)
27 (60%) 22 (59·5%)
Anti-metabolites 
(azathioprine)
9 (20%) 4 (10·8%)
Corticosteriods 44 (97·8%) 37 (100%)
HLA mismatchesa 3·0 (0–6) 3·0 (0–6) P = 0·86
CMV serostatus acceptor P = 0·74
Negative 17 (37·8%) 11 (29·7%)
Positive 22 (48·9%) 20 (54·1%)
Unknown 6 (13·3%) 6 (16·2%)
CMV serostatus donor P = 0·62
Negative 15 (33·3%) 14 (37·8%)
Positive 18 (40%) 11 (29·7%)
Unknown 12 (26·7%) 12 (32·4%)
ESRD diagnosis P = 0·04
Polycystic kidney 11 (24·4%) 5 (13·5%)
Hypertension 8 (17·8%) 7 (18·9%)
Diabetic nephropathy – 7 (18·9%)
Glomerulonephritis 7 (15·6%) 4 (10·8%)
Other 19 (42·2%) 14 (37·8%)
Dialysis 
pretransplantation
P = 0·83
Yes (PD/HD) 22 (48·9%) 19 (51·4%)
No 23 (51·1%) 18 (48·6%)
aMedian and range.
cSCC  =  cutaneous squamous cell carcinoma; Tx  =  transplantation; 
ATG  =  anti-thymocyte globulin; MMF  =  mycophenolate mofetil; 
HLA  =  human leucocyte antigen; CMV  =  cytomegalovirus; ESDR  =   
end-stage renal disease; PD = peritoneal dialysis; HD = haemodialysis.
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B+ cells was not significantly different between the cSCC 
patients and non-cSCC patients (Supporting information, 
Fig. S4a), nor was degranulation of the T cells, as deter-
mined by CD107a staining (Supporting information, 
Fig. S4b).
SerpinB9 expression was also measured in the T cells. 
Gating strategy for serpinB9 is presented in the Supporting 
information, Fig. S5. The percentage of CD3+ serpinB9+ 
cells before stimulation was not significantly different 
between cSCC and non-cSCC patients (Fig. 4a). After 
stimulation, serpinB9 expression in all T cells was up-
regulated to 98·2% (93·0–99·0%) for the cSCC patients and 
99·1% (97·2–99·7%) for the non-cSCC patients, and this 
was significantly different even though the differences were 
small (P = 0·006; Fig. 4b). When analysing serpinB9 expres-
sion in the CD4+ and CD8+ population separately, we 
observed that the percentage of CD4+ serpinB9+ cells was 
significantly lower in the cSCC patients than in the non-
cSCC patients after stimulation (Fig. 4c). In the CD8+ 
population this difference was not observed (Fig. 4d). These 
results show that the CD4+ population is the main con-
tributor to the difference observed in the total T cell 
population.
Discussion
In this study, we demonstrate high DNA methylation 
of SERPINB9 in circulating T cells before the clinical 
onset of cSCC in kidney transplant recipients and, in a 
different patient cohort, during recurrent post-transplant 
cSCC. These data identify high DNA methylation of 
SERPINB9 as a novel risk factor for development of both 
de-novo and subsequent post-transplant cSCC. In addi-
tion, T cells of cSCC patients were unable to fully up-
regulate serpinB9 expression in vitro, which might provide 
insight into the role of the peripheral immune system 
in the development of an cSCC in kidney transplant 
recipients.
In a previous study, where we identified DMRs associ-
ated with post-transplant cSCC before transplantation [23], 
SERPINB9 was not significantly different between T cells 
of future cSCC patients and non-cSCC patients. Thus, 
differences in SERPINB9 DNA methylation that identify 
patients at risk for cSCC arise after kidney transplanta-
tion. Kidney transplantation and the use of immunosup-
pressive therapy probably affect DNA methylation profiles 
of the T cells [35]. However, as we demonstrated high 
SERPINB9 methylation in patients before and after the 
development of a de-novo post-transplant cSCC, it seems 
a persistent risk factor for cSCC after transplantation.
Based on the differential DNA methylation of 
SERPINB9, one could expect differences in mRNA expres-
sion of SERPINB9. Nevertheless, when SERPINB9 mRNA 
expression was measured in the T cells, this was not 
significantly different between cSCC patients and non-
cSCC patients. This is comparable to findings by Ryer 
et al. [36], who identified higher methylation of the 
same region within SERPINB9 in PBMCs of patients 
with abdominal aortic aneurysm. Despite the differential 
DNA methylation, they also did not detect a difference 
in mRNA expression. This is due most probably to the 
intragenic location of the DMR, outside the promoter 
region of SERPINB9. The effect of intragenic DNA 
methylation on gene expression is still debated [37], 
although in this study we demonstrated an inverse cor-
relation between intragenic SERPINB9 DNA methylation 
and mRNA expression in the T cells of non-cSCC 
patients. Surprisingly, this inverse correlation was absent 
in the T cells of cSCC patients. This illustrates a dis-
turbed transcriptional regulation of SERPINB9 in cSCC 
patients and a clear difference between these two patient 
groups.
Table 3. Resulting differentially methylated regions of the discovery analysis
Annotated to: Genomic location (hg19) Length DMR
No. of 
probes Function Regional P-value Effect size DMR state
1 SERPINB9 chr6:2891973–2892153 180 bp 5 Granzyme B 
inhibitor
1·09 × 10–13 0·14 Hyper
2 VTRNA2-1 chr5:135415948–135416614 666 bp 12 Inhibitor of protein 
kinase R
1·40 × 10–10 0·11 Hyper
3 VTRNA2-1 chr5:135414858–135415259 401 bp 4 Inhibitor of protein 
kinase R
1·90 × 10–8 0·07 Hyper
4 PIF1 chr15:65116194–65116558 364 bp 3 ATP metabolism 1·36 × 10–7 –0·05 Hypo
5 APC2 chr19:1465962–1466163 201 bp 2 Signalling pathway 
regulation
1·48 × 10–7 0·08 Hyper
6 RPH3AL chr17:151914–152351 437 bp 6 Tumour suppressor 3·39 × 10–7 –0·07 Hypo
7 AC144450.2 chr2:1609660–1609833 173 bp 2 LincRNA 3·15 × 10–6 0·08 Hyper
DMR = differentially methylated region; chr = chromosome; bp = base pair.
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Previous studies have shown that higher expression 
of serpinB9 increased the potency of cytotoxic T cells 
[21,22]. We observed a slightly lower expression of 
serpinB9 in the T cells of our cSCC patients, which 
was due mainly to the CD4 compartment of the T 
cells, although it is questionable whether a difference 
Fig. 1. Genomic characteristics of differentially methylated regions (DMR) 1–3. The chromatin state specific for primary T cells of SERPINB9 (a) and 
VTRNA2-1 (b) is depicted with the cytosine–phosphate–guanine (CpG) islands below in purple. The location of the DMRs are highlighted by the 
orange dotted lines. The graphs present the raw beta-values (y-axis) and the genomic location of the single CpGs (x-axis), cutaneous squamous cell 
carcinoma (cSCC) patients are depicted in red and the non-cSCC in green. The transcription start site (TSS) is the promoter of a gene; enhancers are 
locations that bind gene-activating or repressing proteins such as transcription factors and repressed polycomb represents inactive DNA.
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between 98 and 99% serpinB9-positive cells is biologi-
cally relevant. In addition, the regulation of serpinB9 
seems independent from the regulation of cytotoxic 
markers of T cells, as we did not identify differences 
in the expression of granzyme B and CD107a between 
cSCC patients and non-cSCC patients. SerpinB9 is an 
intracellular protein inactivating granzyme B once it is 
released into the cytoplasm [38], and therefore serpinB9 
exerts its effect on cytotoxicity only after granzyme B 
is synthesized to its active form. The absence of differ-
ences in cytotoxicity which, in most cases, is restricted 
to the CD8+ T cells, and the SERPINB9 DNA methyla-
tion difference in the CD4+ T cells may lead to the 
conclusion that the CD4+ T cells are the population of 
interest in post-transplant cSCC.
DNA methylation of SERPINB9 might represent a future 
treatment target for cSCC in transplant recipients. It would 
be interesting to decrease SERPINB9 DNA methylation 
in cSCC patients to the level observed in non-cSCC patients 
and study whether that affects future cSCC development 
in those patients. DNA methylation can be edited by use 
of the CRISPR/cas9 system, a technique called ‘epigenetic 
editing’ [39]. Although this novel technology is far from 
a clinical application, it is a promising concept for the 
future. Additionally, this approach will reveal whether 
Fig. 3. Relative mRNA expression of SERPINB9 (a) in cutaneous squamous cell carcinoma (cSCC) versus non-cSCC patients, (b) as correlated to 
SERPINB9 DNA methylation (x-axis) within all patients, (c) within the cSCC patients and (d) within the non-cSCC patients.
Fig. 2. DNA methylation in T cells of cutaneous squamous cell 
carcinoma (cSCC) and non-cSCC patients for regions 1 and 2 of 
SERPINB9 measured by pyrosequencing. **P < 0·01.
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SERPINB9 DNA methylation plays a causal role in cSCC 
development or whether it is a consequence of another, 
as yet unknown, mechanism leading to post-transplant 
cSCC development.
We are aware that the single-centre design and small 
sample size may be a limitation of this study. Details 
such as sun exposure were unknown, and dosages of 
immunosuppression were often adjusted or immunosup-
pressive regimens were changed during the course of 
post-transplant treatment. It was therefore not possible 
to take these factors into account. Nevertheless, we show 
a promising proof-of-concept that studying DNA meth-
ylation of SERPINB9 in peripheral T cells can identify 
kidney transplant recipients at risk for cSCC. The disturbed 
transcriptional regulation of SERPINB9 and the lower 
protein expression of serpinB9 warrant further investiga-
tion to fully understand the relation with cSCC develop-
ment in kidney transplant recipients.
Together, these findings demonstrate that DNA meth-
ylation, transcriptional regulation and protein expression 
of serpinB9 differ between cSCC and non-cSCC patients. 
This identifies a novel risk factor for the development of 
post-transplant cSCC and may provide mechanistic insight 
into the role of circulating T cells in cSCC development. 
Future studies will identify whether serpinB9 plays a causal 
role in cSCC development and if it is a suitable treatment 
target to prevent cSCC development after kidney 
transplantation.
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Fig. 4. Quantified flow cytometry data on serpinB9 expression by T cells. (a) Percentage of T cells that expressed serpinB9 before stimulation in the 
cutaneous squamous cell carcinoma (cSCC) and non-cSCC patients and (b) after stimulation. (c) Percentage of CD4 T cells and (d) CD8 T cells that 
expressed serpinB9 after stimulation in the cSCC and non-cSCC patients. **P < 0·01.
F. S. Peters et al.
© 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for 
Immunology, Clinical and Experimental Immunology, 197: 341–351
350
References
 1 Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors 
after solid organ transplantation. Int J Cancer 2009; 
125:1747–54.
 2 van de Wetering J, Roodnat JI, Hemke AC, Hoitsma AJ, Weimar 
W. Patient survival after the diagnosis of cancer in renal 
transplant recipients: a nested case–control study. 
Transplantation 2010; 90:1542–6.
 3 Mittal A, Colegio OR. Skin cancers in organ transplant recipients. 
Am J Transplant 2017; 17:2509–30.
 4 Hanlon A, Colegio OR. The cutting edge of skin cancer in 
transplant recipients: scientific retreat of international transplant 
skin cancer collaborative and skin cancer in organ transplant 
patients Europe. Am J Transplant 2014; 14:1012–5.
 5 Bouwes Bavinck JN, Feltkamp MCW, Green AC et al. Human 
papillomavirus and posttransplantation cutaneous squamous 
cell carcinoma: a multicenter, prospective cohort study. Am J 
Transplant 2018; 18:1220–30.
 6 Wisgerhof HC, Edelbroek JR, de Fijter JW et al. Subsequent 
squamous- and basal-cell carcinomas in kidney-transplant 
recipients after the first skin cancer: cumulative incidence and 
risk factors. Transplantation 2010; 89:1231–8.
 7 Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, 
subversion and escape: the role of regulatory T cells in cancer 
progression. Clin Exp Immunol 2013; 171:36–45.
 8 Feldmeyer L, Ching G, Vin H et al. Differential T-cell subset 
representation in cutaneous squamous cell carcinoma arising 
in immunosuppressed versus immunocompetent individuals. 
Exp Dermatol 2016; 25:245–7.
 9 Bauer C, Abdul Pari AA, Umansky V et al. T-lymphocyte 
profiles differ between keratoacanthomas and invasive squamous 
cell carcinomas of the human skin. Cancer Immunol 
Immunother 2018; 67:1147–57.
 10 Crespo E, Fernandez L, Lucia M et al. Effector antitumor and 
regulatory T cell responses influence the development of 
nonmelanoma skin cancer in kidney transplant patients. 
Transplantation 2017; 101:2102–10.
 11 Lai C, August S, Albibas A et al. OX40+ regulatory T cells 
in cutaneous squamous cell carcinoma suppress effector T-cell 
responses and associate with metastatic potential. Clin Cancer 
Res 2016; 22:4236–48.
 12 Clark RA, Huang SJ, Murphy GF et al. Human squamous cell 
carcinomas evade the immune response by down-regulation 
of vascular E-selectin and recruitment of regulatory T cells. J 
Exp Med 2008; 205:2221–34.
 13 Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune 
cells in the tumor microenvironment. Nat Immunol 2013; 
14:1014–22.
 14 Mahmoud SM, Paish EC, Powe DG et al. Tumor-infiltrating 
CD8+ lymphocytes predict clinical outcome in breast cancer. 
J Clin Oncol 2011; 29:1949–55.
 15 Feil R, Fraga MF. Epigenetics and the environment: emerging 
patterns and implications. Nat Rev Genet 2012; 13:97–109.
 16 Jones MJ, Fejes AP, Kobor MS. DNA methylation, genotype 
and gene expression: who is driving and who is along for the 
ride? Genome Biol 2013; 14:126.
 17 Feinberg AP. The key role of epigenetics in human disease 
prevention and mitigation. N Engl J Med 2018; 
378:1323–34.
 18 Kaiserman D, Bird PI. Control of granzymes by serpins. Cell 
Death Differ 2010; 17:586–95.
 19 Classen CF, Bird PI, Debatin KM. Modulation of the granzyme 
B inhibitor proteinase inhibitor 9 (PI-9) by activation of 
lymphocytes and monocytes in vitro and by Epstein–Barr virus 
and bacterial infection. Clin Exp Immunol 2006; 143:534–42.
 20 Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. 
Cytotoxic lymphocytes require granzyme B for the rapid 
induction of DNA fragmentation and apoptosis in allogeneic 
target cells. Cell 1994; 76:977–87.
 21 Hirst CE, Buzza MS, Bird CH et al. The intracellular granzyme 
B inhibitor, proteinase inhibitor 9, is up-regulated during 
accessory cell maturation and effector cell degranulation, and 
its overexpression enhances CTL potency. J Immunol 2003; 
170:805–15.
 22 Azzi J, Ohori S, Ting C et al. Serine protease inhibitor-6 
differentially affects the survival of effector and memory 
alloreactive CD8–T cells. Am J Transplant 2015; 15:234–41.
 23 Peters FS, Peeters AMA, Mandaviya PR et al. Differentially 
methylated regions in T cells identify kidney transplant patients 
at risk for de novo skin cancer. Clin Epigenetics 2018; 10:81.
 24 van Iterson M, Tobi EW, Slieker RC et al. MethylAid: visual 
and interactive quality control of large Illumina 450k datasets. 
Bioinformatics 2014; 30:3435–7.
 25 Huber W, Carey VJ, Gentleman R et al. Orchestrating high-
throughput genomic analysis with Bioconductor. Nat Methods 
2015; 12:115–21.
 26 RCoreTeam. r: A Language and Environment for Statistical 
Computing. Vienna, Austria: R Foundation for Statistical 
Computing; 2016.
 27 Pidsley R, Wong CCY, Volta M, Lunnon K, Mill J, Schalkwyk 
LC. A data-driven approach to preprocessing Illumina 450K 
methylation array data. BMC Genom 2013; 14:293.
 28 Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-
effects models using lme4. J Stat Softw 2015; 67:48.
 29 Boer K, de Wit LEA, Peters FS et al. Variations in DNA 
methylation of interferon gamma and programmed death 1 in 
allograft rejection after kidney transplantation. Clin Epigenetics 
2016; 8:116.
 30 Pedersen BS, Schwartz DA, Yang IV, Kechris KJ. Comb-p: 
software for combining, analyzing, grouping and correcting 
spatially correlated P-values. Bioinformatics 2012; 28:2986–8.
 31 Šidák Z. Rectangular confidence regions for the means of 
multivariate normal distributions. J Am Stat Assoc 1967; 
62:626–33.
 32 Tost J, Gut IG. DNA methylation analysis by pyrosequencing. 
Nat Protoc 2007; 2:2265–75.
Disrupted regulation of serpinB9 in circulating T cells
© 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society 
for Immunology, Clinical and Experimental Immunology, 197: 341–351
351
 33 Peters FS, Peeters AMA, Hofland LJ, Betjes MGH, Boer K, 
Baan CC. Interferon-gamma DNA methylation is affected by 
mycophenolic acid but not by tacrolimus after T-cell activation. 
Front Immunol 2017; 8:822.
 34 Roadmap Epigenomics Consortium, Kundaje A, Meuleman W 
et al. Integrative analysis of 111 reference human epigenomes. 
Nature 2015; 518:317–30.
 35 Chu AY, Tin A, Schlosser P et al. Epigenome-wide association 
studies identify DNA methylation associated with kidney 
function. Nat Commun 2017; 8:1286.
 36 Ryer EJ, Ronning KE, Erdman R et al. The potential role of 
DNA methylation in abdominal aortic aneurysms. Int J Mol 
Sci 2015; 16:11259–75.
 37 Jones PA. Functions of DNA methylation: islands, start sites, 
gene bodies and beyond. Nat Rev Genet 2012; 13:484–92.
 38 Heutinck KM, ten Berge IJ, Hack CE, Hamann J, Rowshani 
AT. Serine proteases of the human immune system in health 
and disease. Mol Immunol 2010; 47:1943–55.
 39 de Groote ML, Verschure PJ, Rots MG. Epigenetic editing: targeted 
rewriting of epigenetic marks to modulate expression of selected 
target genes. Nucleic Acids Res 2012; 40:10596–613.
Supporting Information
Additional supporting information may be found in the 
online version of this article at the publisher’s web site: 
Fig. S1. Detailed time schedule of (a) the discovery patient 
cohort and (b) the second patient cohort. On the Y-axis are 
all the cSCC patients and their matched controls and on 
the X-axis is the time in months from the transplantation 
(Tx) onwards.
Fig. S2. Correlation between methylation values obtained 
by pyrosequencing and microarray. (a) XY plot of DMR 1 
(SERPINB9) with array values on the X-axis and pyro val-
ues on the Y-axis. (b) Detailed graph for each of the 5 sites 
within DMR 1 (SERPINB9) with in red the cSCC patients 
and in green the non-cSCC patients. (c) XY plot of DMR 2 
(VTRNA2-1) with pyro values on the X-axis and array val-
ues on the Y-axis. (d) Detailed graph for each of the 3 sites 
within DMR 2 (VTRNA2-1) with in red the cSCC patients 
and in green the non-cSCC patients.
Fig. S3. Gating strategy for granzyme B expression and 
CD107a by T cells. Representative examples of (a) lym-
phocyte gate from forward scatter (FSC) and sideward 
scatter (SSC), (b) living T cells gated from 7AAD-CD3 
staining, (c) granzyme B+ cells gated within the living 
T cells at 0 hours, (d) granzyme B+ cells gated within the 
living T cells at 6 hours, (e) CD107a+ cells gated within the 
living T cells at 0 hours, (f) CD107a+ cells gated within 
the living T cells at 6 hours, (g) isotype control in green 
and granzyme B stained sample in red at 0 hours and 
(h) isotype control in green and granzyme B stained sam-
ple in red at 6 hours.
Fig. S4. Quantified flow cytometry data on granzyme B 
and CD107a expression by T cells. (a) Percentage of T cells 
that expressed granzyme B before and after stimulation in 
the cSCC and non-cSCC patients. (b) Percentage of T cells 
that expressed CD107a before and after stimulation in the 
cSCC and non-cSCC patients.
Fig. S5. Gating strategy for serpinB9 expression by T 
cells. Representative examples of (a) lymphocyte gate from 
forward scatter (FSC) and sideward scatter (SSC), (b) living 
T cells gated from 7AAD-CD3 staining, (c) serpinB9+ cells 
gated within the living T cells at 0 hours, (d) serpinB9+ 
cells gated within the living T cells at 6 hours, (e) isotype 
control in green and serpinB9 stained sample in red at 0 
hours and (f) isotype control in green and serpinB9 stained 
sample in red at 6 hours.
Table S1. PCR and sequence primers of genes for validation.
